Biased Agonism: Renewing GPCR’s Targetability for the Drug Discovery

Ravinder Reddy Gaddam; Ajit Vikram

doi:10.1007/978-981-15-5534-3_5

Back

Book chapter

Biased Agonism: Renewing GPCR’s Targetability for the Drug Discovery

Ravinder Reddy Gaddam and Ajit Vikram

Drug Discovery and Development, pp.125-136

Springer Singapore

02/16/2021

DOI: 10.1007/978-981-15-5534-3_5

View Online

Abstract

The G-protein-coupled receptors (GPCRs) elicit functionally distinct signalings, and the biased agonist preferentially activates one over other. The conceptual framework of biased agonism theoretically renews the targetability of GPCRs for drug development, aiming to achieve desired pharmacological effects at minimal adverse outcomes.

Biased agonism

Drug targets

GPCRs

Details

Title: Subtitle: Biased Agonism: Renewing GPCR’s Targetability for the Drug Discovery
Creators: Ravinder Reddy Gaddam - Roy J. and Lucille A. Carver College of Medicine
Ajit Vikram - Roy J. and Lucille A. Carver College of Medicine
Resource Type: Book chapter
Publication Details: Drug Discovery and Development, pp.125-136
Publisher: Springer Singapore; Singapore
DOI: 10.1007/978-981-15-5534-3_5
Language: English
Date published: 02/16/2021
Academic Unit: Fraternal Order of Eagles Diabetes Research Center; Cardiovascular Medicine; Internal Medicine
Record Identifier: 9984363422702771

Metrics

10 Record Views